Lava Therapeutics NV

The European biotech environment seems to be enjoying something of a revival but it has been a chastening week for three of the continent’s cancer-focused companies that have been forced to look at al

More than halfway through the biopharma year, there is no question that 2023 has proven very difficult for many early stage biotech companies, due to heavy ‘right sizing,’ job losses and even company

The market for initial public offerings in the US looks like it might be waking up from a month and a half nap with one biopharmaceutical company making it through the IPO window in mid-June and three

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Astellas, Pantherna Expand mRNA Re